{"product_id":"zerpidio-serplulimab","title":"Zerpidio (Serplulimab) Зерпидио (серплулимаб)","description":"Serplulimab, a recombinant humanised anti-PD-1 monoclonal antibody (mAb) injection, is the first innovative monoclonal antibody developed by Henlius.\r\n\u003cul\u003e\r\n \t\u003cli\u003eSerplulimab sold under the brand name 汉斯状\u003csup\u003e®\u003c\/sup\u003e in china.\u003c\/li\u003e\r\n \t\u003cli\u003eSerplulimab sold under the brand name Hetronifly\u003csup\u003e®\u003c\/sup\u003e in Euro.\u003c\/li\u003e\r\n \t\u003cli\u003eSerplulimab sold under the brand name Zerpidio\u003csup\u003e®\u003c\/sup\u003e in other Place.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nIt has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of Small Cell Lung Cancer (SCLC). Its marketing application for the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) is under review by the EMA.\r\n\r\nSerplulimab was launched in \u003cspan class=\"xn-location\"\u003eChina\u003c\/span\u003e under the trade name HANSIZHUANG（汉斯状） in \u003cspan class=\"xn-chron\"\u003eMarch 2022\u003c\/span\u003e and has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC), ES-SCLC, and esophageal squamous cell carcinoma (ESCC).\r\n\r\n\u003cspan class=\"legendSpanClass\"\u003e\u003cspan class=\"xn-chron\"\u003eOct. 27, 2023\u003c\/span\u003e\u003c\/span\u003e - Intas Pharmaceuticals Limited (\"Intas\") has entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the development and commercialisation of serplulimab for \u003cspan class=\"xn-location\"\u003eEurope\u003c\/span\u003e and \u003cspan class=\"xn-location\"\u003eIndia\u003c\/span\u003e markets.\r\n\r\n\u003cspan class=\"legendSpanClass\"\u003e\u003cspan class=\"xn-chron\"\u003eJan. 25, 2024 \u003c\/span\u003e\u003c\/span\u003eZerpidio\u003csup\u003e®\u003c\/sup\u003e start set sail for \u003cspan class=\"xn-location\"\u003eIndonesia\u003c\/span\u003e. Zerpidio® in Indonesia for the treatment of extensive stage small cell lung cancer (ES-SCLC).","brand":"Henlius Biopharmaceutical Company","offers":[{"title":"Default Title","offer_id":44797952393259,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-3152.png?v=1787022175","url":"https:\/\/xomeds.com\/products\/zerpidio-serplulimab","provider":"XOMEDS","version":"1.0","type":"link"}